Clinical

Using biomarkers to guide treatment decisions are increasingly being leveraged across various cancers, and metastatic colorectal cancer (mCRC) is no exception. However, the positivity rates of these biomarkers can differ across different patient characteristics, according to a recent study.

According to the researchers, their study is the first to assess the impact of oral targeted therapies among a large number of adolescents and young adults (AYA) patients with chronic lymphocytic leukemia (CLL).

Right ventricular end-systolic elastance to end-systolic arterial elastance coupling in excess of 0.68 was linked with preserved right ventricular function and better survival outcomes in patients with heart failure with reduced ejection fraction and secondary pulmonary hypertension.

A novel biologic for severe asthma reduced exacerbations by 56%, according to a study published Wednesday in The New England Journal of Medicine.

This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus.

A roundup of cancer news from the ESMO Breast Cancer Virtual Congress 2021, which took place last week and was covered by OncLive®.

Strategies for improving outcomes across hematologic cancers and solid tumors range from addressing cytokine release syndrome and neurotoxicity mediators, immune rejection, on-target off-tumor toxicity, post-infusion control limitation, and immunosuppressive tumor microenvironment.

BK virus–specific T cells from healthy donors were an effective and safe off-the-shelf treatment for patients with leukemia or lymphoma who developed a painful and common complication after allogeneic hematopoietic stem cell transplantation.

Biomarkers are being used in patients with cancer to target treatments that will work best. Interviews with OncLive® highlight how biomarkers are being used in colorectal and bladder cancer.

Using acitretin in combination with secukinumab resulted in nearly complete or total relief for 3 patients with severe psoriasis, according to a case study.

Intravitreal dexamethasone implants stabilized, but did not improve, vision for most patients with macular edema due to retinal vein occlusion (RVO).

A roundup of diabetes news you may have missed from across MJH Life Sciences™.

In a first-of-its kind study, young children undergoing heart surgery had similar results regardless of whether they received levosimendan intravenously or via inhalation.

A novel prediction model is developed that accurately predicts preterm birth in a timely manner among pregnant women in Medicaid without preterm-birth history.

Using transcranial sonography, researchers uncovered a potential imaging biomarker for depression among migraineurs.

Laryngeal hypersensitivity may be a key factor in refractory and unexplained cough.

In a minority-predominant patient population, a standardized pathway for total knee arthroplasty was associated with improved outcomes with no change in postoperative complication rates.

Researchers used data fromThe Environmental Determinants of Diabetes in the Young study to assess whether age impacts risk of T1D onset.

New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.

In a review, researchers examined potential mechanisms contributing to the hereditary nature of migraine.

The current standard calls for bone marrow biopsies, which are invasive and costly.

Last year, a data monitoring committee halted the DAPA-CKD trial when it found the evidence of efficacy was overwhelming, after it was shown the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes.

Despite the FDA approving 29 biosimilars, none have achieved interchangeability status. Boehringer Ingelheim thinks its adalimumab biosimilar, Cyltezo, may be the first.

About 1 in 3 patients experienced adverse drug reactions in the 2 new safety studies, aligning with earlier reports.

Blacks and Hispanics were underrepresented in relation to their US racial distribution in clinical trials for ophthalmology drug approvals from 2000 to 2020.